Document 0849
 DOCN  M9440849
 TI    Evaluation of the genotoxic potential of selected anti-AIDS treatment
       drugs at clinical doses in vivo in mice.
 DT    9404
 AU    Motimaya AM; Subramanya KS; Curry PT; Kitchin RM; Department of
       Dermatology, CBRC, Harvard Medical School,; Charlestown, MA 02129.
 SO    Toxicol Lett. 1994 Feb 1;70(2):171-83. Unique Identifier : AIDSLINE
       MED/94126844
 AB    Six anti-AIDS drugs were assessed for in vivo genotoxicity and
       cytotoxicity at human clinical doses with the mouse bone marrow
       micronucleus assay. These included four dideoxynucleosides
       (azidothymidine, dideoxycytidine, dideoxyadenosine, and dideoxyinosine),
       an anthracycline antibiotic (doxorubicin), and a chelating agent
       (D-penicillamine). Cytological analysis of the mouse bone marrow cells
       revealed: (i) The dideoxynucleosides and D-penicillamine failed to
       induce significant number of micronuclei, and except for one of the five
       doses of dideoxyinosine, none of the dideoxynucleosides were cytotoxic
       at the doses tested. (ii) Doxorubicin induced micronuclei in a
       dose-dependent manner which was statistically significant at 4-times the
       clinical dose but was not cytotoxic at any of the doses tested.
 DE    Acquired Immunodeficiency Syndrome/*DRUG THERAPY  Animal  Antiviral
       Agents/*TOXICITY/THERAPEUTIC USE  Bone Marrow/CYTOLOGY/DRUG EFFECTS
       Dideoxynucleosides/*TOXICITY/THERAPEUTIC USE  Doxorubicin/TOXICITY
       Female  Male  Mice  Micronucleus Tests  Mutagens/*TOXICITY
       Penicillamine/TOXICITY  Support, Non-U.S. Gov't  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).